MetLife Investment Management’s UroGen Pharma URGN Stock Holding History

MetLife Investment Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$915K	Buy	24,865 +1,539	+7%	+$41.7K	﹤0.01%	1573
2026 Q1	$419K	Buy	23,326 +881	+4%	+$17.7K	﹤0.01%	1835
2025 Q4	$526K	Sell	22,445 -321	-1%	-$6.96K	﹤0.01%	1776
2025 Q3	$454K	Hold	22,766	–	–	﹤0.01%	1853
2025 Q2	$312K	Hold	22,766	–	–	﹤0.01%	1936
2025 Q1	$252K	Hold	22,766	–	–	﹤0.01%	2077
2024 Q4	$242K	Buy	22,766 +2,727	+14%	+$32.6K	﹤0.01%	2201
2024 Q3	$254K	Hold	20,039	–	–	﹤0.01%	2161
2024 Q2	$336K	Buy	20,039 +5,413	+37%	+$77K	﹤0.01%	1940
2024 Q1	$219K	Hold	14,626	–	–	﹤0.01%	2150
2023 Q4	$219K	Buy	14,626 +4,223	+41%	+$54.8K	﹤0.01%	2195
2023 Q3	$146K	Hold	10,403	–	–	﹤0.01%	2376
2023 Q2	$108K	Buy	+10,403	New	+$115K	﹤0.01%	2631
2021 Q4	–	Sell	-7,354	Closed	-$124K	–	2553
2021 Q3	$124K	Buy	+7,354	New	+$117K	﹤0.01%	2346
2021 Q2	–	Sell	-8,654	Closed	-$169K	–	2489
2021 Q1	$169K	Sell	8,654 -1,336	-13%	-$28.4K	﹤0.01%	2141
2020 Q4	$180K	Hold	9,990	–	–	﹤0.01%	2032
2020 Q3	$193K	Hold	9,990	–	–	﹤0.01%	1886
2020 Q2	$261K	Hold	9,990	–	–	﹤0.01%	1745
2020 Q1	$178K	Hold	9,990	–	–	﹤0.01%	1768
2019 Q4	$333K	Hold	9,990	–	–	﹤0.01%	1680
2019 Q3	$238K	Buy	+9,990	New	+$327K	﹤0.01%	1845

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MetLife Investment Management's URGN Position: Q2 2026 in Review

MetLife Investment Management increased its UroGen Pharma (URGN) stake by 6.6% in Q2 2026, buying an estimated $41.7K and bringing the position to 24,865 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

MetLife Investment Management first reported a position in URGN in Q3 2019 and has held it in 21 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

MetLife Investment Management held 24,865 shares of UroGen Pharma worth $915K as of Q2 2026.
MetLife Investment Management bought 1,539 UroGen Pharma shares in Q2 2026, an estimated $41.7K.
UroGen Pharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1573 holding.
MetLife Investment Management first reported a position in UroGen Pharma in Q3 2019 and has held it in 21 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.